


Antiplatelet Therapy With Special Focus on Potent Agents











Antiplatelet Therapy With Special Focus on Potent Agents 15 October 2021


Level of consciousness	Facial paresis	NIHSS	STROKE	IMPACTE
LOC questions	Motor arm	SCORE	SEVERITY	BRAIN DENSITY
LOC commands	Motor leg	0	No Stroke	
Best gaze	Limb ataxia	0 - 4	Minor Stroke	
Visual fields	Sensory	5 – 15	Moderate Stroke	
Best language	Dysarthria	16-20	Moderate to	1
	nd inattention	21 - 42	Severe Stroke Severe Stroke	


ABCD2 Risk Stratification Score

A	Age	≥60 years	1 point				
В	Blood pressure	≥140/90 mm Hg	1 point				
C	Clinical features	Unilateral weakness	2 points				
Speech imp	airment without weakness		1 point				
D	Duration	<u>>60 minutes</u>	2 points				
		10-59 minutes	1 point				
D	Diabetes	Presence of diabetes mellitus	1 point				
		ABCD ² score	2-day risk (%)	7-day risk (%)	90-day risk (%)		
		0-3 (low risk)	1.0	1.2	3.1		5
		4–5 (moderate risk)	4.2	5.9	9.8		0C0E 1
		6-7 (high risk)	8.1	11.7	17.8		מז טבטב ומם בנסט מ
						<i>modici</i>	5












Antiplatelet Therapy With Special Focus on Potent Agents














٧
































		RINCE stuc			
Stroke recurrence	e at 90 days, by cause:				
	Trial participants (No	with event/total No (%))	_ Hazard ratio		
Cause of stroke*	Ticagrelor/aspirin (n=336)	Clopidogrel/aspirin (n=339)	(95% CI)*	Ρ	P for interaction
Large artery atherosclerosis	9/151 (6.0)	20/153 (13.1)	0.45 (0.20 to 0.98)	0.04	0.13
Non-large artery atherosclerosis	10/124 (8.1)	10/136 (7.4)	1.10 (0.46 to 2.63)	0.84	-



		E study		
Effect of ticagrelor/aspirin versus clopidos	grel/aspirin on effi	cacy and safety outco	omes in PRINCE trial:	
	Trial participants (I	No with event/total No (%))	Hazard ratio or risk ratio	P
Outcomes	Ticagrelor/aspirin	Clopidogrel/aspirin	- (95% CI)	r
Primary safety outcomes				
Major bleeding	5/336 (1.5)	4/339 (1.2)	1.27 (0.34 to 4.72)	0.72
Major, fatal, life threatening bleeding	4/336 (1.2)	3/339 (0.9)	1.35 (0.30 to 6.03)	0.69
Fatal bleeding	1/336 (0.3)	1/339 (0.3)	1.01 (0.06 to 16.13)	1.00
Intracranial hemorrhage	3/336 (0.9)	2/339 (0.6)	1.27 (0.34 to 4.72)	0.72
Major, other	1/336 (0.3)	1/339 (0.3)	1.01 (0.06 to 16.18)	0.99
Minor bleeding	11/336 (3.3)	8/339 (2.4)	1.40 (0.56 to 3.47)	0.47
Major or minor bleeding	16/336 (4.8)	12/339 (3.5)	1.36 (0.64 to 2.88)	0.42
Minimal bleeding	64/336 (19.0)	36/339 (10.6)	1.86 (1.24 to 2.80)	0.003
Any bleeding	75/336 (22.3)	48/339 (14.2)	1.65 (1.15 to 2.37)	0.007
Other safety outcomes				
Respiratory, thoracic, and mediastinal disorders	22/336 (6.5)	0/339 (0.0)	_	< 0.001
Dyspnea	14/336 (4.2)	0/339 (0.0)	_	< 0.001
Epistaxis	6/336 (1.8)	0/339 (0.0)		0.04

15 October 2021





/	CHANCE & POINTS (Clopidogrel + ASA)	THALES (Ticagrelor + ASA)		NCE II vs Ticagrelor) + AS
Rate of stroke	6.54 %	5.14 %		
Rate of Ischemic stroke	6.30 %	5.00 %	٨/٣ %	۵/۴%
Moderate-to-severe bleeding rates	0.60 %	0.65 %	۴/۸ %	۳٫۵ %
Duration of DAPT therapy	21 & 90 days	30 days	90 days	

	SO	CR/	ATES	•			
a randor	<u> </u>	<u> </u>			al		
	Ticagrelor (r	n=6589)*	Aspirin (n=6	610)†	Hazard ratio (95% CI)‡	p value	p value for interaction
	Number of patients	Event proportion (KM estimate)	Number of patients	Event proportion (KM estimate)	(55% с.)+		Interaction
Primary endpoint							
Stroke, myocardial infarction, or death							0.017
With ipsilateral extracranial or intracranial stenosis	103 (6.7%)	6.7%	147 (9.6%)	9.4%	0.68 (0.53-0.88)	0.003	
Without ipsilateral extracranial or intracranial stenosis	339 (6.7%)	6.8%	350 (6.9%)	6.9%	0.97 (0.84-1.13)	0.72	
Secondary endpoints							
Ischaemic stroke	200						0.12
With ipsilateral extracranial or intracranial stenosis	98 (6.4%)	6.4%	131 (8.5%)	8-3%	0.73 (0.56-0.95)	0.02	
Without ipsilateral extracranial or intracranial stenosis	287 (5.7%)	5.8%	310 (6.1%)	6.1%	0.93 (0.79-1.09)	0.37	
All strokes	657 C	144	0.42	2	22	9223	0.12
With ipsilateral extracranial or intracranial stenosis	98 (6.4%)	6.4%	132 (8.6%)	8.4%	0.72 (0.56-0.94)	0.02	
Without ipsilateral extracranial or intracranial stenosis	292 (5.8%)	5.9%	318 (6.3%)	6-3%	0.92 (0.79-1.08)	0.31	

Conclusion

- Ticagrelor inhibits platelet function more than clopidogrel especially in patients with CYP2C19 loss of function allele.
- prevalence of the CYP2C19 loss of function allele is high especially in Asian populations.
- If a patient had a thromboembolic event while on Clopidogrel, may be he has a loss of function mutation, consider Ticagrelor as an alternative.
- Ticagrelor seems to have better efficacy in patients with atherosclerotic origin.

 Considering new antiplatelet agents (such as Ticagrelor) could be alternatives specially for those carriers with CYP2C19 loss of function alleles.



Antiplatelet Therapy With Special Focus on Potent Agents

15 October 2021

econdary Stroke Prevention	COR	LOE
or patients with non-cardioembolic AIS, the use of antiplatelet agents rather than oral nticoagulation is recommended to reduce the risk of recurrent stroke and other ardiovascular events.	I.	A
or early secondary prevention in patients with non-cardioembolic AIS, the selection of an ntiplatelet agent should be individualized on the basis of patient risk factor profiles, cost, lerance, relative known efficacy of the agents, and other clinical characteristics.	I	C-EO

2021 AHA/ASA Guidelines		
Terican American Heart Stroke		
Recommendations for Intracranial Large Artery Atherosclerosis	COR	LOE
In patients with recent (within 24 hours) minor stroke or high-risk TIA and concomitant ipsilateral >30% stenosis of a major intracranial artery, <u>the addition of ticagrelor 90 mg</u> twice a day to aspirin for up to 30 days might be considered to further reduce recurrent stroke risk.	llb	B-NR
Recommendations for Antithrombotic Medications	COR	LOE
For patients with recent (< 24 hours) minor to moderate stroke (NIHSS score \leq 5), high-risk TIA (ABCD2 score \geq 6), or symptomatic intracranial or extracranial ³ 30% stenosis of an artery that could account for the event, <u>DAPT with ticagrelor plus aspirin for 30 days may be considered</u> to reduce the risk of 30-day recurrent stroke but may also increase the risk of serious bleeding events, including ICH.	llb	B-SR
		بكنكر